Insight Molecular Diagnostics Inc.
IMDX Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 26, 2026
$3.00
KIRA · Stoqly’s AI analyst, in plain words
- Insight Molecular Diagnostics Inc. had $4.1M of revenue in fiscal 2025, up 115.6% on the year before. Over five years, revenue changed +27.2% a year on average.
- Its operating margin was −1,260.8%, up 1,984.4 pts: of every 100 in sales, about −1,261 is left after running the business.
- Insight Molecular Diagnostics Inc. lost $50.2M in fiscal 2025.
- Free cash flow was −$25.4M in fiscal 2025, −625.6% of revenue.
Market cap
$110M
P/E
—
Revenue
$4.1M
Net income
−$50.2M
Free cash flow
−$25.4M
Operating margin
−1,260.8%
Insight Molecular Diagnostics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+115.6%
Yes. Sales grew 115.6% last year.
Does it make a profit?
−1,238.5%
No. It lost money last year.
Does profit turn into cash?
−625.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Insight Molecular Diagnostics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Insight Molecular Diagnostics Inc.
- CIK
- 0001642380
Insight Molecular Diagnostics Inc. · IMDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.2M | $1.0M | $1.5M | $1.9M | $4.1M |
| Revenue growth | 80.8% | −56.4% | 56.9% | 25.1% | 115.6% |
| Net interest income | −$0.2M | −$0.1M | −$0.1M | −$0.1M | −$0.1M |
| Gross margin | 64.6% | −1.9% | 27.5% | 39.3% | 56.7% |
| Operating margin | −2,444.3% | −1,878.6% | −1,672.4% | −3,245.1% | −1,260.8% |
| Net income | −$64.1M | −$72.9M | −$27.8M | −$60.7M | −$50.2M |
| Net margin | −2,916.2% | −7,609.8% | −1,848.4% | −3,225.0% | −1,238.5% |
| Diluted EPS | −$0.72 | −$13.25 | −$3.75 | −$4.66 | −$1.65 |
| Cash | |||||
| Cash from operations | −$35.9M | −$45.6M | −$23.3M | −$20.7M | −$22.2M |
| Capital expenditure | $2.2M | $4.3M | $0.3M | $0.5M | $3.2M |
| Free cash flow | −$38.2M | −$49.9M | −$23.6M | −$21.2M | −$25.4M |
| FCF margin | −1,737.4% | −5,209.6% | −1,570.6% | −1,127.3% | −625.6% |
| Share count change | 35.7% | 6,131.7% | 38.1% | 70.8% | 133.2% |
| Debt and strength | |||||
| Cash and short-term investments | $32.9M | $20.0M | $9.4M | $8.6M | $11.6M |
| Shareholders' equity | $65.2M | $34.3M | $20.5M | −$12.3M | −$31.5M |
| Current ratio | 2.8x | 2.1x | 1.5x | 1.6x | 1.3x |
| Returns and quality | |||||
| Return on equity | −129.9% | −146.5% | −101.5% | −1,480.7% | — |
| Piotroski F-score | 4 | 1 | 4 | 4 | 3 |
| Altman Z'' | −4.3 | −8.2 | −14.1 | −43.7 | −63.8 |
Insiders bought, 12 months
$5.7M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Insight Molecular Diagnostics Inc. · IMDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.00 a share, the company is worth $110M.
Source: SEC EDGAR XBRL filings (CIK 0001642380). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.